24/7 Wall Street
16 Jul 2026, 11:40 UTC · 1h ago
What Investors Don't Understand About Abbott Laboratories
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
16 Jul 2026, 11:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Abbott completed a $21 billion acquisition of Exact Sciences, expected to generate approximately $3 billion in incremental sales in 2026. — Significant inorganic growth through a major acquisition typically boosts long-term revenue projections and expands market share in diagnostics.
+0.60CEO Robert Ford projects the global continuous glucose monitor (CGM) market will expand from 10-12 million current users to 70-80 million. — A massive projected increase in the Total Addressable Market (TAM) for a core growth engine suggests significant long-term upside.
+0.50Abbott shares are trading approximately 29% below the analyst consensus buy target and 32.1% lower over one year despite four consecutive EPS beats. — A strong disconnect between fundamental performance (EPS beats) and price action suggests the stock may be undervalued.
+0.40Continue reading
6 related stories
Top 2 movers · tap to explore
The Nutrition segment revenue fell 6.0% to $2.02 billion, reflecting a decline in a core legacy business area. — Revenue declines in a key segment create a drag on overall growth and maintain negative sentiment among some investors.
-0.20Which stocks this story touches
The company has posted four consecutive EPS beats, strong growth in medical devices, and a strategic acquisition of Exact Sciences.
Mentioned as a competitive threat to Abbott's continuous glucose monitoring market share.
Mentioned only as a benchmark global giant in the context of a sponsored ad.
[a_to_b] Abbott closed a $21 billion acquisition of Exact Sciences.
[b_to_a] Exact Sciences became a subsidiary of Abbott following the acquisition.
[mutual] Both companies compete in the continuous glucose monitoring (CGM) market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Newsfile Corp
1h ago
